‹ Home
Exported

OD2A Innovative Surveillance CoP Workgroup Resource Repository

ABOUT THIS COMMUNITY OF PRACTICE In partnership with the National Center for Injury Prevention and Control (NCIPC), the Council of State and Territorial Epidemiologists (CSTE) hosts this community of practice among OD2A-funded jurisdictions currently conducting innovative surveillance projects. This OD2A Innovative Surveillance Community of Practice consists of 3 focused workgroups that provide a forum for peer discussion on cross-cutting topics, methods, and challenges/solutions across jurisdictions. ______________________________________________________________________________________________________________________ USING THIS BASECAMP + This Basecamp is a tool that houses previous call slides/recordings and allows members to engage with peers. + The Q/A section may be used to facilitate connections/discussion among members. Engagement could include posting new questions/discussion topics or replying to peer questions/discussions. + Members are encouraged to share helpful resources for peers. Members may post any publicly available resource in this space. Please do not share any proprietary information or upload private documents. _________________________________________________________________________________________________________ CONTACT US Email staff lead, Danielle Boyd (overdose@cste.org) if you have questions about the Innovative Surveillance CoP or about this basecamp site for the group. Join the Innovative Surveillance CoP Listserve HERE: https://app.smartsheet.com/b/form/4a5b9c8d52294a67ae920fca78c6c111
Megan Toe, CSTEDanielle Boyd, Program Analyst at CSTEMamadou NdiayeFan XiongErin Stokes, Morbidity Science Officer, CDC/NCIPC/DOPCailyn Lingwall, Program Analyst at CSTELizette BrenesMarcus Rennick, Consultant at Kahuina ConsultingEmily HostermanStephen Liu, Health ScientistDesiree MustaquimClaire NguyenStella TsaiKara ManchesterStacey Hoferka Jensen +80 others
Posted by Christina Galardi ·

Emerging Substances

Has anyone created a syndrome/case definition for either hospital or EMS data for xylazine? We have anecdotally heard increases in this substance but are not able to use SUDORS/mortality data past 2020 at this time and do not have a centralized lab database, which might be our best sources, so we are looking at alternatives in other datasets.

Comments & Events

Rishi Kowalski, Opioid Epidemiologist IV, Cook County Department of Public Health Rishi Kowalski, Opioid Epidemiologist IV, Cook County Department of Public Health
Hi Christina - are you a member of the NSSP CoP Slack that the CDC runs? If not I'm happy to ask about a xylazine syndrome definition there. My intuition is that one doesn't exist at the moment for NSSP ESSENCE or EMS data (I'll also check Biospatial) and we'd likely have to rely on confirmatory testing or drug checking data in the absence of mortality data. 
Notified 78 people
Christina Galardi Christina Galardi
I'm not a member of that Slack if you don't mind inquiring. I likewise haven't seen anything built in Biospatial but they may have suggestions. I agree that lab data would be best, but we are just trying to use what we have!
Rishi Kowalski, Opioid Epidemiologist IV, Cook County Department of Public Health Just asked!
Notified 78 people
Shannon Casillas Shannon Casillas
Hi Christina,
To join the NSSP CoP #drug-overdose_use slack channel, you can request access here: Request to Join NSSP CoP Slack (qualtrics.com). I am not aware of any xylazine syndrome definitions, but the Slack channel is a great place to seek input from other jurisdictions. 
Please let me know how else we can help!
Shannon, CDC 
Notified 78 people